Unlocking the potential of oral SERDs in HER2+/ER+ breast cancer

Description

In Ireland, breast cancer accounts for 30 per cent of all female cancer incidence and is the second most common invasive cancer cause of death. 1 Despite the high incidence, prognosis for many breast cancer cases is increasing year-on-year, with the latest Irish data reporting a five-year survival rate of 88 per cent. 1 A critical challenge still exists in the treatment of breast cancer recurrence and metastasis, both of which are closely linked to treatment resistance.